| Medical and Health Sciences | Lifetime | 152 | DE 3 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 67 | DE 5 | 99.99 |
| Cardiology and Cardiovascular Medicine | Lifetime | 26 | DE 1 | 99.98 |
| Surgery | Lifetime | 556 | DE 25 | 99.48 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 205 | DE 7 | 99.39 |
| Nephrology | Lifetime | 799 | DE 36 | 87.66 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 9 | DE 1 | 99.96 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 36 | DE 2 | 99.62 |
| Surgery | 2021-2025 | 416 | DE 20 | 96.85 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 756 | DE 35 | 90.32 |
| Blood Pressure and Hypertension Studies | Lifetime | 12 | DE 1 | 99.91 |
| Heart Rate Variability and Autonomic Control | Lifetime | 9 | DE 1 | 99.89 |
| Heart rate and cardiovascular health | Lifetime | 1 | DE 1 | 99.82 |
| Heart Failure Treatment and Management | Lifetime | 24 | DE 1 | 99.90 |
| Cardiovascular Function and Risk Factors | Lifetime | 95 | DE 2 | 99.80 |
| Cardiac electrophysiology and arrhythmias | Lifetime | 93 | DE 8 | 99.64 |
| Hormonal Regulation and Hypertension | Lifetime | 62 | DE 10 | 99.56 |
| Cardiac pacing and defibrillation studies | Lifetime | 76 | DE 4 | 99.70 |
| Diabetes Treatment and Management | Lifetime | 120 | DE 5 | 99.46 |
| Receptor Mechanisms and Signaling | Lifetime | 237 | DE 13 | 99.26 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 82 | DE 4 | 98.79 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 315 | DE 19 | 99.17 |
| Cardiovascular Health and Disease Prevention | Lifetime | 202 | DE 6 | 98.88 |
| Renal and Vascular Pathologies | Lifetime | 166 | DE 8 | 98.73 |
| Cardiovascular Issues in Pregnancy | Lifetime | 156 | DE 17 | 98.42 |
| Lipoproteins and Cardiovascular Health | Lifetime | 277 | DE 9 | 98.75 |
| Medication Adherence and Compliance | Lifetime | 94 | DE 3 | 98.12 |
| Cardiac Imaging and Diagnostics | Lifetime | 687 | DE 54 | 98.94 |
| Sodium Intake and Health | Lifetime | 71 | DE 3 | 98.61 |
| Cardiac Arrhythmias and Treatments | Lifetime | 528 | DE 36 | 98.63 |
| Cardiac Fibrosis and Remodeling | Lifetime | 114 | DE 19 | 98.12 |
| Cardiac Ischemia and Reperfusion | Lifetime | 330 | DE 30 | 97.82 |
| Mechanical Circulatory Support Devices | Lifetime | 492 | DE 37 | 97.97 |
| Cardiac Health and Mental Health | Lifetime | 343 | DE 10 | 97.60 |
| Renin-Angiotensin System Studies | Lifetime | 230 | DE 24 | 97.54 |
| Cardiac Structural Anomalies and Repair | Lifetime | 894 | DE 68 | 97.67 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 539 | DE 32 | 96.66 |
| Angiogenesis and VEGF in Cancer | Lifetime | 977 | DE 79 | 95.01 |
| Sexual function and dysfunction studies | Lifetime | 547 | DE 21 | 95.14 |
| Pharmacology and Obesity Treatment | Lifetime | 766 | DE 39 | 92.55 |
| Potassium and Related Disorders | Lifetime | 428 | DE 18 | 92.37 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 222 | DE 31 | 90.83 |
| Migraine and Headache Studies | Lifetime | 968 | DE 70 | 91.19 |
| Pericarditis and Cardiac Tamponade | Lifetime | 584 | DE 34 | 88.48 |
| Vitamin K Research Studies | Lifetime | 922 | DE 62 | 81.94 |
| Sex and Gender in Healthcare | Lifetime | 527 | DE 21 | 78.14 |
| GDF15 and Related Biomarkers | Lifetime | 908 | DE 63 | 74.00 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 5 | DE 1 | 99.82 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 15 | DE 1 | 99.31 |
| Heart Failure Treatment and Management | 2021-2025 | 27 | DE 1 | 99.80 |
| Diabetes Treatment and Management | 2021-2025 | 38 | DE 2 | 99.64 |
| Heart rate and cardiovascular health | 2021-2025 | 1 | DE 1 | 98.67 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 106 | DE 7 | 99.23 |
| Pancreatic function and diabetes | 2021-2025 | 73 | DE 3 | 98.25 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 98 | DE 5 | 98.69 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 55 | DE 2 | 97.28 |
| Sodium Intake and Health | 2021-2025 | 32 | DE 2 | 95.97 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 469 | DE 49 | 96.65 |
| Renal and Vascular Pathologies | 2021-2025 | 181 | DE 3 | 91.97 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 944 | DE 85 | 93.11 |
| Hormonal Regulation and Hypertension | 2021-2025 | 323 | DE 28 | 89.94 |
| Medication Adherence and Compliance | 2021-2025 | 194 | DE 5 | 88.52 |
| Potassium and Related Disorders | 2021-2025 | 121 | DE 5 | 89.92 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 238 | DE 13 | 85.03 |
| Cardiovascular Issues in Pregnancy | 2021-2025 | 402 | DE 19 | 85.33 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 761 | DE 36 | 81.69 |
| Electrolyte and hormonal disorders | 2021-2025 | 361 | DE 22 | 77.38 |
| Pharmaceutical Economics and Policy | 2021-2025 | 573 | DE 18 | 78.38 |
| Migraine and Headache Studies | 2021-2025 | 927 | DE 54 | 74.21 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 419 | DE 27 | 70.13 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 724 | DE 60 | 45.33 |
| Oropharyngeal Anatomy and Pathologies | 2021-2025 | 323 | DE 13 | 42.88 |